Shahrin Ahmed: Multiple myeloma treatment with Darzalex Faspro has been approved by the FDA

Shahrin Ahmed, Medical Specialist at the Canadian Cancer Society, shared a post on X:

“Multiple myeloma treatment with Darzalex Faspro has been approved by the FDA.

The FDA has granted approval to Johnson and Johnson’s Darzalex Faspro (daratumumab and hyaluronidase-fihj) and its partners, Bortezomib, Lenalidomide, and D-VRd, for use in patients for induction and consolidation. An Autologous Stem Cell Transplant (ASCT) is possible for the patient who recently was diagnosed with multiple myeloma (MM).

D-VRd’s efficacy and safety were compared in a Phase III trial that led to the approval. Patients with MM eligible for ASCT are treated with VRd during induction and consolidation, but not VRd during induction and consolidation.

The clinical course of multiple myeloma is highly individualized and varied for each patient. Patients need treatment options at diagnosis and throughout the course of their disease through innovation and therapies that utilize different targets and combinations.

Almost 20 percent of patients reported experiencing adverse reactions with D-VRd, according to the report released. Other ailments that can affect the peripheral nervous system include fatigue, edema, pyrexia, upper respiratory infection, constipation, diarrhea, musculoskeletal pain, insomnia, and rash.

Compelling evidence of the benefits of adding D-VRd can be found in the efficacy data and established safety and tolerability profile for this new quadruplet regimen. In the context of autologous stem cell transplantation, deepening responses and prolonging remissions can be accomplished by comparison of initial diagnosis data to VRd.”

Source: Shahrin Ahmed/X

More posts by Shahrin Ahmed in OncoDaily.